FTSE 100 news / Companies and sectors / Pharma and healthcare / 18 October 2026
Pharma and healthcare: sector news on Sunday 18 October 2026
Average tone +2.8 (slightly positive) across 3 companies with relevant coverage, from 9 stories.
Company by company
| Company | Tone | Stories | What the coverage was about |
|---|---|---|---|
| AstraZeneca | +5.7 | 6 | Coverage was mainly about AstraZeneca opening a new corporate office in Mumbai and announcing a new collaboration with insitro. |
| GSK | +0.7 | 2 | Coverage was thin, limited to a profile of chief executive Luke Miels and a routine note on the share price ahead of the next Xetra session. |
| Convatec | +2.0 | 1 | Coverage was limited to Morgan Stanley keeping its GBP 2.88 price target on Convatec stock. |
| Haleon | – | 0 | |
| Smith & Nephew | – | 0 |
Strongest stories in the sector
- +7.5 AstraZeneca announces new insitro collaboration - ad-hoc-news.de
New collaboration with insitro supports its R&D pipeline. - +6.7 AstraZeneca Strengthens India Presence with New Mumbai Corporate Office
Strengthened India presence through new corporate office. - +6.7 AstraZeneca India opens new Mumbai office for next phase of growth through innovation
New Mumbai office signals investment in India growth. - +6.3 AstraZeneca opens new Mumbai corporate office
New Mumbai corporate office shows expansion in India. - +4.2 Summit Therapeutics (SMMT) Stock Fair Value Edges Higher After AstraZeneca Deal And Trial Focus
Summit stock story references AstraZeneca deal; modestly positive, AZN secondary. - +2.0 Morgan Stanley keeps GBP 2.88 target for ConvaTec stock - ad-hoc-news.de
Morgan Stanley maintains its price target, a mildly supportive analyst note. - +0.8 AstraZeneca is a British behemoth. Why is it turning to America?
Feature on AstraZeneca's strategic shift towards America; broadly neutral. - +0.8 Luke Miels: Flinders University Biologist, Global Pharma Leader, and Chief Executive Officer of GSK
Profile of GSK's chief executive; factual, mildly positive. - +0.3 GSK stock heads into the next Xetra session at EUR 22.03 - ad-hoc-news.de
Routine share price note with no clear direction.
Pharma and healthcare: every day · FTSE 100 overview for the day